Product Description
Mechanisms of Action: ERBB3 Inhibitor
Novel Mechanism: Yes
Modality: Antibody Drug Conjugate
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Daiichi Sankyo
Company Location: TOKYO M0 103-8426
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Australia, Austria, Belgium, Bulgaria, Canada, China, France, Germany, Hong Kong, Italy, Japan, Korea, Netherlands, Norway, Poland, Portugal, Singapore, South Korea, Spain, Switzerland, Taiwan, United Kingdom, United States, Unknown Location
Active Clinical Trial Count: 27
Highest Development Phases
Phase 3: Non-Small-Cell Lung Cancer|Squamous Cell Carcinoma
Phase 2: Bladder Cancer|Brain Cancer|Breast Cancer|Cervical Cancer|Colorectal Cancer|Endometrial Cancer|Esophageal Cancer|Gastrointestinal Cancer|Head and Neck Cancer|Melanoma|Meningeal Cancer|Oncology Solid Tumor Unspecified|Ovarian Cancer|Pancreatic Cancer|Prostate Cancer|Spinal Cord Cancer|Uterine Cancer
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| VALENTINE | P2 |
Active, not recruiting |
Breast Cancer |
2029-11-17 |
|
| SOLTI-2103 | P2 |
Not yet recruiting |
Breast Cancer |
2029-10-17 |
|
| ICARUSBREAST02 | P2 |
Recruiting |
Breast Cancer |
2027-09-01 |
|
| N23HDX | P2 |
Not yet recruiting |
Squamous Cell Carcinoma|Non-Small-Cell Lung Cancer |
2027-05-01 |